ClinicalTrials.gg

Program

cadisegliatin

Also written as “GK1-399 (formerly TTP399)”, “Cadisegliatin 800 mg QD” and “TTP399”.

Its studies are mostly in Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2, led by vTv Therapeutics.

Furthest: phase 3, since Mar 13, 20245 company-led studies, 2 open or runningNext primary completion: Apr 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
vTv Therapeutics52 open or runningphase 3since Mar 13, 2024Nov 15, 2011Apr 2027phase 3 · NCT06334133

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 15, 2011First study: phase 2 study in Diabetes Mellitus, Type 2First studyNCT01474083 · 248 enrolled · United States
  2. Mar 27, 2015Phase 2 study in Diabetes Mellitus, Type 2NCT02405260 · 190 enrolled · United States
  3. Oct 31, 2017Phase 2 study in Diabetes Mellitus, Type 1NCT03335371 · 115 enrolled · United States
  4. Mar 13, 2024Phase 3 study in Diabetes Mellitus, Type 1NCT06334133 · 150 enrolled · United States, Puerto Rico
  5. May 15, 2026Phase 2 study in Diabetes Mellitus, Type 1NCT07616206 · 40 planned · United States

Ahead

  1. Apr 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 1NCT06334133
  2. Jun 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 1NCT07616206

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07616206Diabetes Mellitus, Type 1 · United States2RecruitingJun 202740
NCT06334133Diabetes Mellitus, Type 1 · United States, Puerto Rico3Active, not recruitingApr 2027150
NCT03335371Diabetes Mellitus, Type 1 · United States2CompletedDec 20, 2019115
NCT02405260Diabetes Mellitus, Type 2 · United States2CompletedJul 2016190
NCT01474083Diabetes Mellitus, Type 2 · United States2CompletedAug 2012248

How it is read

Names in the registry

  • “GK1-399 (formerly TTP399)”, 3 entries
  • “Cadisegliatin 800 mg QD”, 2 entries
  • “TTP399”, 2 entries
  • “Cadisegliatin 800 mg BID”, 1 entry
  • “TTP399 400 mg”, 1 entry

Codes read as this program: TTP399.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.